Literature DB >> 26045296

Late Effects of Treatment of Pediatric Central Nervous System Tumors.

Erika Roddy1, Sabine Mueller2.   

Abstract

Central nervous system tumors represent the most common solid malignancy in childhood. Improvement in treatment approaches have led to a significant increase in survival rates, with over 70% of children now surviving beyond 5 years. As more and more children with CNS tumors have longer survival times, it is important to be aware of the long-term morbidities caused not only by the tumor itself but also by tumor treatment. The most common side effects including poor neurocognition, endocrine dysfunction, neurological and vascular late effects, as well as secondary malignancies, are discussed within this article.
© The Author(s) 2015.

Entities:  

Keywords:  brain tumor; chemotherapy; late effect; radiation therapy; stroke

Mesh:

Year:  2015        PMID: 26045296     DOI: 10.1177/0883073815587944

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  26 in total

Review 1.  Neurological Complications of Pediatric Cancer.

Authors:  Elizabeth C Neil; Sharyu Hanmantgad; Yasmin Khakoo
Journal:  J Child Neurol       Date:  2015-12-29       Impact factor: 1.987

2.  Presentation and symptom interval in children with central nervous system tumors. A single-center experience.

Authors:  Chiara Stocco; Chiara Pilotto; Eva Passone; Agostino Nocerino; Raffaello Tosolini; Anna Pusiol; Paola Cogo
Journal:  Childs Nerv Syst       Date:  2017-08-14       Impact factor: 1.475

3.  Determinants of social competence in pediatric brain tumor survivors who participated in an intervention study.

Authors:  Maru Barrera; Eshetu G Atenafu; Fiona Schulte; Ute Bartels; Lillian Sung; Laura Janzen; Joanna Chung; Danielle Cataudella; Kelly Hancock; Amani Saleh; Douglas Strother; Dina McConnell; Andrea Downie; Juliette Hukin; Shayna Zelcer
Journal:  Support Care Cancer       Date:  2017-04-14       Impact factor: 3.603

Review 4.  Molecular Genetics and Targeted Therapies for Paediatric High-grade Glioma.

Authors:  Kathrine S Rallis; Alan Mathew George; Anna Maria Wozniak; Carola Maria Bigogno; Barbara Chow; John Gerrard Hanrahan; Michail Sideris
Journal:  Cancer Genomics Proteomics       Date:  2022 Jul-Aug       Impact factor: 3.395

5.  CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018.

Authors:  Quinn T Ostrom; Mackenzie Price; Katherine Ryan; Jacob Edelson; Corey Neff; Gino Cioffi; Kristin A Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2022-09-06       Impact factor: 13.029

Review 6.  Clinical trials in pediatric neuro-oncology: what is missing and how we can improve.

Authors:  Lennox Byer; Cassie Kline; Sabine Mueller
Journal:  CNS Oncol       Date:  2016-09-12

7.  Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.

Authors:  Erika Roddy; Katherine Sear; Erin Felton; Benita Tamrazi; Karen Gauvain; Joseph Torkildson; Benedict Del Buono; David Samuel; Daphne A Haas-Kogan; Josephine Chen; Robert E Goldsby; Anuradha Banerjee; Janine M Lupo; Annette M Molinaro; Heather J Fullerton; Sabine Mueller
Journal:  Neuro Oncol       Date:  2016-08-18       Impact factor: 12.300

Review 8.  Case-based review: pediatric medulloblastoma.

Authors:  Cassie N Kline; Roger J Packer; Eugene I Hwang; David R Raleigh; Steve Braunstein; Corey Raffel; Pratiti Bandopadhayay; David A Solomon; Mariam Aboian; Soonmee Cha; Sabine Mueller
Journal:  Neurooncol Pract       Date:  2017-08-11

9.  A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Authors:  Jason Fangusaro; Arzu Onar-Thomas; Tina Young Poussaint; Shengjie Wu; Azra H Ligon; Neal Lindeman; Olivia Campagne; Anu Banerjee; Sridharan Gururangan; Lindsay B Kilburn; Stewart Goldman; Ibrahim Qaddoumi; Patricia Baxter; Gilbert Vezina; Corey Bregman; Zoltan Patay; Jeremy Y Jones; Clinton F Stewart; Michael J Fisher; Laurence Austin Doyle; Malcolm Smith; Ira J Dunkel; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2021-10-01       Impact factor: 12.300

10.  Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial.

Authors:  Jason Fangusaro; Duane A Mitchell; Mehmet Kocak; Giles W Robinson; Patricia Ann Baxter; Eugene I Hwang; Jianping Huang; Arzu Onar-Thomas; Ira J Dunkel; Maryam Fouladi; Katherine E Warren
Journal:  Pediatr Blood Cancer       Date:  2020-10-07       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.